Perioperative Anticoagulation Management Flashcards
___, ___, and ___ are the leading causes of anticoagulation treatment.
AF, DVT, and PE
Aspirin (Acetylsalicylic Acid)
This agent is the most commonly prescribed antiplatelet drug for the prevention of cardiovascular disorders. Its mechanism of action is the irreversible inhibition of _______.
The cyclooxygenase (COX) 1 and 2 enzymes.
Regarding the MOA of aspirin, the action of COX is necessary for the conversion of ______ to ________.
This is rapidly converted to several bioactive prostanoids, including ________, a potent vasoconstrictor, and an inductor of platelet aggregation.
Arachidonic acid
Prostaglandin (PG) H2
Thromboxane A2
Despite the short half-life of aspirin (3 to 6 hours), its irreversible effects will last for the complete lifetime of the platelet (__ to ___ days).
After the interruption of aspirin therapy, recovery of platelet function depends on its turnover (approximately __% per day).
8 to 9 days
10%
The effect of NSAIDs on platelet function is considered a short-term effect that normalizes within _____ days; nonetheless, this can vary between drugs in the class.
For short-acting drugs like ibuprofen, diclofenac, and indomethacin, 50% of platelet function is restored ____ hours after the last dose and normalized after _____ hours.
Three days
Six hours; normalize in 24 hours.
Thienopyridines (_____ and _____)
Clopidogrel and Prasugrel
Thienopyridines (Clopidogrel and Prasugrel)
These are inhibitors of the _______ receptor, also called the ______ receptor, in platelets.
Adenosine diphosphate (ADP) receptor, also called the P2Y12 receptor. This is an irreversible mechanism.
Physiologically, the union of ADP with its receptor on platelets increases levels of intracellular calcium and activates the _____ platelet receptor that promotes the stabilization of the platelet clot through fibrinogen bonds.
GpIIB/IIIa
Due to the irreversible mechanism of action of thienopyridines, it is recommended to interrupt these drugs ______ days before non-cardiac elective surgery.
5 to 7
Non-thienopyridines (Ticagrelor and Cangrelor)
Ticagrelor is a reversible, non-competitive ____ analog that binds to a G-protein in the _____ receptor, preventing its activation and signaling.
Cangrelor is a direct, reversible, and intravenously administered drug that inhibits the _____ receptor.
ATP analog; P2Y12
P2Y12 receptor
After a loading dose of ticagrelor, the maximum antiplatelet effect is achieved within 2 hours, plasma half-life is 8 to 12 hours, and steady-state concentration in 2 to 3 days. Due to the reversible effect of ticagrelor on platelets, it is recommended to be suspended ___ days before surgery.
Five days
Cangrelor can inhibit 95% to 100% of platelet activity within the first two minutes of administration; the plasma half-life of cangrelor (3 to 6 minutes) allows recovery of 80% to 90% platelet function within ________ of discontinuing the intravenous infusion.
60 to 90 minutes
Vitamin K Antagonists (Warfarin, Acenocoumarol, Phenprocoumon)
These are also called coumarins. The most recognized and widely used drug of this group is warfarin, which has been available for more than 50 years. The mechanism of action of warfarin is the inhibition of the ___________ enzyme, responsible for the cyclical conversion of _____ vitamin K to a _____ state.
The latter is necessary as a cofactor for the ________ of glutamic acid at the N-terminus of coagulation factors. Without ______ residues, clotting factors II, VII, IX, and X cannot bind to the ________ necessary for normal activation.
2,3 epoxide reductase
Oxidized; reduced
Carboxylation
Gamma carboxyglutamate
Divalent calcium
Why is it that there is a temporary hypercoagulable state after starting warfarin?
The inhibition of carboxylation also affects the production of protein C and S anticoagulants. This creates a transient procoagulant state that can be explained by the shorter half-life of these anticoagulants (8 and 30 hours), compared to factor II and factor X (60 and 72 hours). This phenomenon is more frequent, with higher doses of vitamin K antagonists at the beginning of anticoagulation therapy.